ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

HWK-016, MUCIN-16-targeted ADC

A development code.

Its studies are mostly in Endometrial Neoplasms, led by Whitehawk Therapeutics.

Furthest: phase 1, since Mar 9, 20261 company-led study, 1 open or runningNext primary completion: Feb 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Whitehawk Therapeutics11 open or runningphase 1since Mar 9, 2026Mar 9, 2026Feb 2028phase 1 · NCT07470853

Also a collaborator on its studies: Catalyst Pharmaceutical Research.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 9, 2026First study: phase 1 study in Endometrial NeoplasmsFirst studyNCT07470853 · 265 planned · United States

Ahead

  1. Feb 2028Primary completion: phase 1 study in Endometrial NeoplasmsNCT07470853

TargetBeta

MUC16 →read by rule
“HWK-016-101 is a Phase 1 study evaluating HWK-016, a mucin-16 (MUC-16) targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors.”study text, by rule · the study

Other programs on MUC16

ProgramCompanyFurthest phaseStudies
Antibody-drug Conjugate GSK5533524GlaxoSmithKlinephase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07470853Endometrial Neoplasms · United States1RecruitingFeb 2028265

How it is read

Names in the registry

  • “HWK-016, MUCIN-16-targeted ADC”, 1 entry

Codes read as this program: HWK016.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.